Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,849 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Withdrawn No phase listed Observational

Breast Cancer BRCA1 Carriers: a Pilot Study

NCT05062174
View directory record Official record
Conditions
BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
Mifepristone 200 MG, Prophylactic mastectomy
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Not applicable Interventional

The Effect of Low Intensity Exercise on Quality of Life and Hemodynamics in Patients With Permanent Atrial Fibrillation

NCT00680290
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Exercise
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atopic Dermatitis (AD) and Food Allergy

NCT03168113
View directory record Official record
Conditions
Atopic Dermatitis (AD), Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 2 Interventional Results available

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

NCT05312697
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab
Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
19 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

NCT00587223
View directory record Official record
Conditions
Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions
Apligraf, Standard dressing regimen
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
2 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Forward Access to Clinical and Technological Research: Genetic Influences on Cancer and Atopic Dermatitis

NCT04362852
View directory record Official record
Conditions
Eczema/Atopic Dermatitis, Cancer
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

NCT01053247
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Enrolling by invitation No phase listed Observational

Persona SoluTion PPS Femur PMCF

NCT07286513
View directory record Official record
Conditions
Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis, Collagen Disorders, Avascular Necrosis of Femoral Condyle, Valgus Deformity, Varus Deformity, Flexion Deformity of Knee
Interventions
Total knee arthroplasty
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
4
States / cities
Denver, Colorado • Louisville, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

NCT02384460
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101-6.0 cream, Placebo (SD-101-0.0) cream
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
1 Month and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
21
States / cities
Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational

WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)

NCT02692846
View directory record Official record
Conditions
Williams Syndrome, Cardiovascular Disease, Multisystem Developmental Disorder, Elastin Gene Deletion, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

NCT04156191
View directory record Official record
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Rancho Santa Margarita, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

NCT00179959
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Sodium hypochlorite (bleach) baths, Mupirocin ointment, Water, Petrolatum Ointment
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Months to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Study of TDM-180935 in Atopic Dermatitis Patients

NCT06363461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1, TDM-180935 topical vehicle ointment 2
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Rolling Meadows, Illinois • Covington, Louisiana • New Brighton, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Growth Hormone Therapy in Osteogenesis Imperfecta

NCT00001305
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Humatrope
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 16 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

NCT06488742
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus
Interventions
3% kanuka oil
Other
Lead sponsor
Nexgen Dermatologics, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

NCT06268860
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab vial injection, Rocatinlimab prefilled syringe
Drug · Combination Product
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Active, not recruiting Phase 4 Interventional

Bodewell Products for the Treatment of Atopic Dermatitis

NCT05566262
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Bodewell Calming Cream
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Active, not recruiting No phase listed Observational

MElanoma Research Lymph Node Prediction Implementation National_001

NCT04759781
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
SkylineDx
Industry
Eligibility
18 Years and older
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional

A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis

NCT00666302
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
tacrolimus ointment, pimecrolimus cream
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
16 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1 Interventional

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

NCT00101270
View directory record Official record
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

NCT00305695
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Zoledronic Acid
Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
95
States / cities
Scottsdale, Arizona • Tucson, Arizona • Burbank, California + 76 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Withdrawn Phase 2 Interventional

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

NCT03216486
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 21, 2026, 6:59 AM EDT